scholarly journals The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs

2016 ◽  
Vol 21 ◽  
pp. 23-32 ◽  
Author(s):  
Olivia Rossanese ◽  
Suzanne Eccles ◽  
Caroline Springer ◽  
Amanda Swain ◽  
Florence I. Raynaud ◽  
...  
Keyword(s):  
Anticancer Drugs ◽  
Tumor Models ◽  
Preclinical Development ◽  
Audit Trail ◽  
Critical Issues

scholarly journals Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1412
Author(s):  
Maria Grazia Ferraro ◽  
Marialuisa Piccolo ◽  
Gabriella Misso ◽  
Francesco Maione ◽  
Daniela Montesarchio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Anticancer Drugs ◽  
Anticancer Agents ◽  
Preclinical Development ◽  
Cell Death Pathways ◽  
Complex Information ◽  
Ru Complexes ◽  
Therapeutic Alternatives

In this review we have showcased the preclinical development of original amphiphilic nanomaterials designed for ruthenium-based anticancer treatments, to be placed within the current metallodrugs approach leading over the past decade to advanced multitarget agents endowed with limited toxicity and resistance. This strategy could allow for new options for breast cancer (BC) interventions, including the triple-negative subtype (TNBC) with poor therapeutic alternatives. BC is currently the second most widespread cancer and the primary cause of cancer death in women. Hence, the availability of novel chemotherapeutic weapons is a basic requirement to fight BC subtypes. Anticancer drugs based on ruthenium are among the most explored and advanced next-generation metallotherapeutics, with NAMI-A and KP1019 as two iconic ruthenium complexes having undergone clinical trials. In addition, many nanomaterial Ru complexes have been recently conceived and developed into anticancer drugs demonstrating attractive properties. In this field, we focused on the evaluation of a Ru(III) complex—named AziRu—incorporated into a suite of both zwitterionic and cationic nucleolipid nanosystems, which proved to be very effective for the in vivo targeting of breast cancer cells (BBC). Mechanisms of action have been widely explored in the context of preclinical evaluations in vitro, highlighting a multitarget action on cell death pathways which are typically deregulated in neoplasms onset and progression. Moreover, being AziRu inspired by the well-known NAMI-A complex, information on non-nanostructured Ru-based anticancer agents have been included in a precise manner.

Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs

2008 ◽  
Vol 17 (2) ◽  
pp. 197-208 ◽  
Author(s):  
Axel H Schönthal ◽  
Thomas C Chen ◽  
Florence M Hofman ◽  
Stan G Louie ◽  
Nicos A Petasis
Keyword(s):  
Anticancer Drugs ◽  
Preclinical Development ◽  
Inhibitory Function ◽  
Cox 2

Recent advances in herbal nanomedicines for cancer treatment

2020 ◽  
Vol 13 ◽  
Author(s):  
Deepak Pradhan ◽  
Prativa Biswasroy ◽  
Amita Sahu ◽  
Dipak Kumar Sahu ◽  
Goutam Ghosh ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Treatment ◽  
Anticancer Drugs ◽  
Water Solubility ◽  
Large Population ◽  
Huge Number ◽  
Functional Attributes ◽  
Critical Issues ◽  
Development Processes ◽  
Delivery Approach

: Cancer continues to be one of the deadliest diseases that adversely impacts the large population of the world. A stack of scientific documents reflects a huge number of potent plant-based anticancer drugs such as curcumin (CUR), podophyllotoxin, camptothecin (CPT), vincristine, vinblastine, paclitaxel (PTX), etc. that have been integrated into the modern practice of cancer treatment. The demand for natural products raises exponentially as they are generally considered to be safe, and devoid of critical toxic effects at the therapeutic dose when compared to their synthetic counterparts. Despite rising interest towards the potent phytoconstituents, formulation developer faces various challenges in drug development processes such as poor water solubility, low bioavailability, marginal permeability, and nonspecific drug delivery at the target site, etc. Further, adverse drug reaction and multidrug resistance are other critical issues need to be addressed. Nanomedicines owing to their unique structural and functional attributes help to fix the above challenges for improved translational outcomes. This review summarises the prospects and challenges of a nanotechnologybased drug delivery approach for the delivery of plant-based anticancer drugs.

LA-ICP-MS imaging in multicellular tumor spheroids – a novel tool in the preclinical development of metal-based anticancer drugs

Metallomics ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 398-402 ◽  
Author(s):  
Sarah Theiner ◽  
Ekaterina Schreiber-Brynzak ◽  
Michael A. Jakupec ◽  
Markus Galanski ◽  
Gunda Koellensperger ◽  
...  
Keyword(s):  
Anticancer Drugs ◽  
Predictive Power ◽  
Multicellular Tumor Spheroids ◽  
Preclinical Development ◽  
Ms Imaging ◽  
Icp Ms ◽  
Culture Models ◽  
Cell Culture Models ◽  
Dimensional Cell

A novel application of advanced elemental imaging offers cutting edgein vitroassays with more predictive power on the efficacy of anticancer drugs in preclinical development compared to two dimensional cell culture models.

Sign in / Sign up

Export Citation Format

Share Document